Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-43
Closed -$3.9K 321
2024
Q4
$3.9K Hold
43
0.01% 588
2024
Q3
$4.15K Hold
43
0.01% 568
2024
Q2
$3.95K Sell
43
-52
-55% -$4.83K 0.01% 632
2024
Q1
$8.76K Buy
95
+52
+121% +$4.87K 0.01% 520
2023
Q4
$4.09K Hold
43
0.01% 672
2023
Q3
$4.02K Buy
+43
New +$3.97K 0.01% 672

Other funds holding AMED

LGT Financial Advisors's AMED Position: Q1 2025 in Review

LGT Financial Advisors sold out of Amedisys (AMED) in Q1 2025, closing a stake of 43 shares — an estimated $3.9K sold.

LGT Financial Advisors first reported a position in AMED in Q3 2023 and held it in 6 quarters. The position peaked at $8.76K in Q1 2024. 304 funds tracked by Wall St. Rank hold AMED as of Q1 2025.

  • LGT Financial Advisors reported no remaining Amedisys position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 43 Amedisys shares in Q1 2025, an estimated $3.9K.
  • LGT Financial Advisors first reported a position in Amedisys in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's Amedisys position peaked at $8.76K in Q1 2024.
  • 304 funds tracked by Wall St. Rank held Amedisys as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.